| Primary | Percentage of Patients Across Different Lung Function Categories (% FVC (Forced Vital Capacity)) | The distribution of patients across different lung function categories (% FVC serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentage of Patients (%) | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| | | Title | Denominators | Categories |
|---|
| Mild IPF: FVC ≥ 70% | | | | Moderate IPF: FVC between 50% and 69% | | | | Severe IPF: FVC < 50% | | |
| |
| Primary | Percentage of Patients Across Different Lung Function Categories (% DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide)) | The distribution of patients across different lung function categories (% DLCO serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation. | All enrolled patients who met the selection criteria.Include only those patients DLCO value who has been answered in the case report form (CRF). | Posted | | Number | | Percentage of Patients (%) | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Demographic Baseline Characteristics - Age at the Time of Treatment Initiation | The age of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Mean | Standard Deviation | Years | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Duration of the Disease | Duration of the disease of IPF patients, calculated as the time elapsed from the date of diagnosis until the start date of treatment with OFEV® (years). | All enrolled patients who met the selection criteria. | Posted | | Mean | Standard Deviation | Years | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With Emphysema | The percentage of patients with emphysema at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With Usual Interstitial Pneumonia (UIP) Histopathological Pattern | The usual interstitial pneumonia (UIP) histopathological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With UIP Radiological Pattern | The UIP radiological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With the Initial Dose of OFEV® | The percentage of patients initiated OFEV® dose of 150 milligram (mg)/ 12 hours (h) and 100 mg/12 h is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Demographic Baseline Characteristics - Weight at the Start of Nintedanib Therapy | The weight of IPF patients at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Mean | Standard Deviation | Kilogram (Kg) | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Demographic Baseline Characteristics - Height at the Start of Nintedanib Therapy | The height of IPF patients at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Mean | Standard Deviation | Centimeters (cm) | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Demographic Baseline Characteristics - Body Mass Index (BMI) at the Start of Nintedanib Therapy | The body mass index (BMI) of IPF patients at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Mean | Standard Deviation | Kilogram/ meter^2 (kg/m^2) | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Demographic Baseline Characteristics - 6-minute Walk Test | The 6-minute walk test of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Mean | Standard Deviation | Meter (m) | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Demographic Baseline Characteristics - Percentage of Patients With Smoking Habit | The percentage of patients with smoking habit at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentage of Participants | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With Dyspnoea | The percentage of patients with dyspnoea at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Partients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With Exacerbations | The percentage of patients with exacerbations of IPF in the year prior to initiating treatment is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | The Clinical Baseline Characteristics - Percentage of Patients With Concomitant Treatments | The percentage of patients taking any concomitant medication at the start of nintedanib therapy is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | Percentage of Patients With Prevalence of Comorbidity (Concomitant Diseases) at the Time of Treatment Initiation. | The percentage of patients with comorbidity (concomitant diseases) at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | Percentage of Patients With Other Concomitant Diseases at the Time of Treatment Initiation. | The percentage of patients with other concomitant diseases at the start of treatment with nintedanib (OFEV®) is presented. | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |
| Secondary | Percentage of Patients Distributed Across Different Lung Function Categories Based on the Reimbursement Threshold (%FVC) | The distribution of patients across different lung function categories based on the reimbursement threshold (FVC >80%, 50-80%, and <50%). | All enrolled patients who met the selection criteria. | Posted | | Number | | Percentages of Patients | | From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days. | | | | ID | Title | Description |
|---|
| OG000 | Total Patients With IPF | The IPF patients who initiated treatment with nintedanib (OFEV®) from 01January2016 up to 07June2018. |
| |